Kevin Lee's most recent trade in Bicycle Therapeutics Plc - ADR was a trade of 3,193 Ordinary Shares done at an average price of $7.4 . Disclosure was reported to the exchange on July 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 7.44 per share. | 02 Jul 2025 | 3,193 | 480,804 | - | 7.4 | 23,756 | Ordinary Shares |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 7.09 per share. | 02 Jul 2025 | 2,268 | 483,997 | - | 7.1 | 16,080 | Ordinary Shares |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.63 per share. | 02 Jun 2025 | 4,747 | 379,665 (1%) | 0% | 3.6 | 17,254 | Common Stock |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 7.48 per share. | 02 Apr 2025 | 3,432 | 486,265 | - | 7.5 | 25,671 | Ordinary Shares |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 8.02 per share. | 02 Apr 2025 | 2,237 | 489,697 | - | 8.0 | 17,941 | Ordinary Shares |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.58 per share. | 03 Mar 2025 | 10,800 | 384,412 (1%) | 0% | 4.6 | 49,433 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 140,000 | 376,950 (1%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 18,262 | 395,212 (1%) | 0% | 0 | Common Stock | |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 308,000 | 308,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 123,200 | 504,064 | - | 0 | Ordinary Shares | |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 14.09 per share. | 02 Jan 2025 | 9,038 | 495,026 | - | 14.1 | 127,345 | Ordinary Shares |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 14.75 per share. | 02 Jan 2025 | 3,092 | 491,934 | - | 14.8 | 45,607 | Ordinary Shares |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.97 per share. | 01 Dec 2024 | 11,431 | 244,450 (0%) | 0% | 9.0 | 102,573 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 8.94 per share. | 01 Dec 2024 | 7,500 | 236,950 (0%) | 0% | 8.9 | 67,073 | Common Stock |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 03 Oct 2024 | 3,212 | 380,864 | - | 22.3 | 71,499 | Ordinary Shares |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 7.22 per share. | 03 Sep 2024 | 7,500 | 255,881 (0%) | 0% | 7.2 | 54,174 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.27 per share. | 03 Sep 2024 | 2,772 | 263,381 (0%) | 0% | 7.3 | 20,150 | Common Stock |
| Logility Supply Chain Solu... | Kevin Lee McInturff | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2024 | 100,000 | 100,000 | - | - | Stock Option | |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 19.64 per share. | 03 Jul 2024 | 3,194 | 384,076 | - | 19.6 | 62,730 | Ordinary Shares |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 6.53 per share. | 11 Jun 2024 | 7,500 | 266,153 (0%) | 0% | 6.5 | 49,008 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 03 Jun 2024 | 2,951 | 273,653 (0%) | 0% | 6.5 | 19,280 | Common Stock |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 23.81 per share. | 03 Apr 2024 | 3,158 | 387,270 | - | 23.8 | 75,192 | Ordinary Shares |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.05 per share. | 01 Mar 2024 | 4,540 | 276,604 (0%) | 0% | 8.1 | 36,552 | Common Stock |
| Health Catalyst Inc | Freeman Kevin Lee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 110,000 | 277,810 (0%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Lee Kevin Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 3,334 | 281,144 (0%) | 0% | 0 | Common Stock | |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 155,000 | 155,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 77,000 | 399,131 | - | 0 | Ordinary Shares | |
| Bicycle Therapeutics Plc -... | Kevin Lee | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 02 Jan 2024 | 8,703 | 390,428 | - | 17.5 | 152,303 | Ordinary Shares |
| Health Catalyst Inc | Lee Kevin Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.45 per share. | 01 Dec 2023 | 2,921 | 167,810 (0%) | 0% | 7.5 | 21,762 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.24 per share. | 01 Jun 2023 | 1,038 | 179,191 (0%) | 0% | 11.2 | 11,666 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 1,819 | 179,665 (0%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.29 per share. | 01 Mar 2023 | 1,569 | 177,846 (0%) | 0% | 14.3 | 22,419 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 1,264 | 180,929 (0%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Growth Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.65 per share. | 01 Dec 2022 | 2,446 | 179,415 (0%) | 0% | 10.6 | 26,049 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2022 | 120,000 | 181,861 (0%) | 0% | 0 | Common Stock |